FERDINANDOS SKOULIDIS to Antineoplastic Agents
This is a "connection" page, showing publications FERDINANDOS SKOULIDIS has written about Antineoplastic Agents.
Connection Strength
0.415
-
Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021 06 24; 384(25):2371-2381.
Score: 0.155
-
Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer. Clin Cancer Res. 2017 Feb 01; 23(3):618-622.
Score: 0.113
-
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 03; 19(3):500-506.
Score: 0.046
-
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet. 2023 03 04; 401(10378):733-746.
Score: 0.044
-
Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021 09; 597(7878):732-737.
Score: 0.040
-
Enterovirus infection of neuronal cells post-Rituximab. Br J Haematol. 2009 Aug; 146(3):333-5.
Score: 0.017